InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.004 0 (0%)+
Announcement
Release
14 Apr 2026 1:00PM
Price at Release
$0.004
Full Release
download
Summary
Percheron Therapeutics Limited announced the completion of its Entitlement Offer, raising $2.2 million to progress its HMBD-002 program. The offer allowed shareholders to purchase new shares with free options, resulting in strong support and full allocation of Shortfall Securities. The funds will support the company's Phase II trial efforts for the HMBD-002 program in CY2026. Blue Ocean Equities and Cygnet Capital managed the transaction, with trading of new shares beginning on April 16, 2026.
Key Points
  • Percheron Therapeutics Limited completed a 2 for 5 Non-Renounceable Entitlement Offer.
  • Raised $2.2 million to progress the HMBD-002 program.
  • Entitlement Offer included New Shares at $0.005 each and free-attaching unlisted options.
  • Strong support from shareholders, raising approximately $0.8 million from existing shareholders.
  • Additional $1.4 million raised from new investors.
  • All applications for Shortfall Securities were granted in full.
  • Blue Ocean Equities and Cygnet Capital served as Joint Lead Managers.
  • New Shares and Options allotment on 15th April 2026, trading commenced on 16th April 2026.
  • HMBD-002 program aims for a Phase II trial in CY2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.